It eventually led to Still being diagnosed with ATTR amyloidosis, a rare genetic condition that causes heart problems, neuropathy, and ligament and tendon troubles. Since his diagnosis in ...

AMVUTTRA® (vutrisiran) product logo ATTR-CM is a devastating, rapidly progressive, and ultimately fatal disease estimated to affect approximately 150,000 people in the U.S. and over 300,000 ...

Next up is the CARDIO-TTRansform trial on transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Could you explain the significance of this trial and its potential to reshape the treatment ...

“We are pleased that the FDA has accepted our sNDA for vutrisiran for the treatment of ATTR with cardiomyopathy – a steadily progressing, debilitating and ultimately fatal disease,” said ...